tbuckley/cabot-search huggingface dataset:
Pituitary carcinoma: The University of Texas MD Anderson Cancer Center experience.
Authors: Fernando Santos Pinheiro, Marta Penas-Prado, Ian E. McCutcheon, Anita Mahajan, Paul D. Brown, Carlos Kamiya-Matsuoka
Journal: Journal of Clinical Oncology (2017)

2068 Background: Pituitary carcinoma (PC) is a rare and aggressive neuroendocrine tumor diagnosed once a pituitary adenoma (PA) becomes metastatic. Although no standard treatment currently exists, surgery, radiation (XRT) and/or chemotherapy are most commonly used. Recently, treatment with temozolomide (TMZ) has shown promising results, although the lack of prospective trials limits accurate outcome assessment. Methods: We describe a single-center multidisciplinary team experience in managing PC patients over a 13-year period (Oct, 2003 to Jan, 2017). Results: A total of 17 patients (9 males) were seen. Median age at diagnosis of PC was 44 years (range 16-82 years) and the median time from PA to PC conversion was 6 years (range 1-29 years). Median follow-up time: 28 months (range 8-158 months) with 7 reported deaths. The majority of PC was hormone-secreting (HS) subtype (n = 12): ACTH (n = 5), PRL (n = 4), FSH/LH (n = 2), GH (n = 1). After PC diagnosis, all pituitary tumors were locally invasive, all underwent at least one resection (mean 2.3) and all received at least one course of XRT alone (IMRT = 76%, SRS = 29%, IMPT = 12%) or concurrent with chemotherapy (18%). Immunohistochemistry showed high Ki-67 labeling index ( &gt; 3%) in 9 (53%) cases. Most cases (n = 14) had metastases to the CNS, 35% of those had combined CNS and systemic foci. Ten (59%) cases underwent focal treatment of metastases, 90% of which underwent XRT. The most common chemotherapy used was TMZ [n = 14 (82%): single agent (n = 10); TMZ+capecitabine (n = 5); concurrent TMZ+XRT (n = 3); concurrent TMZ+XRT with adjuvant TMZ (n = 1)]. The median longest progression-free survival (LPFS) was 18 months (range 4-45 months). TMZ was associated with the chemotherapy-related LPFS in 9 (75%) cases. The 2, 3 and 5 year survival rate was 65%, 53% and 35%, respectively. All patients surviving &gt; 5 years were treated with TMZ (n = 5, 2 survived &gt; 10 years). Two refractory cases are currently on PD-1 inhibitor agent. Eighty percent of non-functioning PC were alive at last follow-up (HS-PC, 58%). Recurrence occurred in 11 (65%) cases. Conclusions: Treatment of PC requires a multidisciplinary approach. Multimodality therapy with surgery, radiation and TMZ was associated with higher survival rates and longer PFS.
Phallogenic Lalorrhea
Authors: CHARLES K. TASHIMA
Journal: Annals of Internal Medicine (1971)

Letters, Comments, and Corrections1 August 1971Phallogenic LalorrheaCHARLES K. TASHIMA, M.D.CHARLES K. TASHIMA, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-75-2-323_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Apparently the Associate Editor could not resist the temptation of invoking the perennial joke about the Japanese inability to differentiate r and l in pronunciation, in his recent comments on the penogram (Ann Intern Med 74:794, 1971).In his search for a less confusing term, he failed to mention phallogram, which I believe is more acceptable because it combines two words of Greek origin and penis comes from the Latin. Need we consider phallo(Gr)hemo(Gr)rheo(Gr)radio(L)gram(Gr)?In the interest of international ecology, I trust this pullulation of "lalorrhea" will remain simply a world prolusion... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: CHARLES K. TASHIMA, M.D.Affiliations: Department of Medicine Grant Hospital of Chicago Chicago, Ill. 60614 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1971Volume 75, Issue 2Page: 323-323KeywordsEcologyPenis ePublished: 1 December 2008 Issue Published: 1 August 1971 PDF downloadLoading ...
Response to commentary of Hultgren et al on 'Aortocoronary-artery-bypass: assessment after 13 years'
Authors: M. E. DeBakey
Journal: JAMA (1979)

THE REPLY of Hultgren et al<sup>1</sup>to our COMMENTARY on the assessment of coronary bypass<sup>2</sup>fails to answer the most serious criticisms of the Veterans Administration Cooperative Study, presents the data from Baylor College of Medicine in an inaccurate, distorted form, and draws yet another set of false conclusions. Our original COMMENTARY was published on Feb 27,1978, only a few weeks after publication of the report of Read and associates.<sup>3</sup>At the time our COMMENTARY was written, we quoted accurately from the only available source of the VA Cooperative Study.<sup>4</sup>The mean follow-up of 21 months was therefore quoted accurately.<sup>4</sup>Read and co-workers<sup>3</sup>subsequently published a follow-up on their patients of up to four years. Only 114 of 332 surgical patients (34%) had, however, been followed up to four years compared with a full five or more years' follow-up for all our patients. To
Increased Incidence of Listeriosis in the Region of Bremen in 1960 and 1961
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ethnic gene profile of genes involved in angiogenesis to predict regional bevacizumab efficacy difference in gastric cancer.
Authors: Takeru Wakatsuki, Wu Zhang, Dongyun Yang, Fotios Loupakis, Mizutomo Azuma, Armin Gerger, Francesco Graziano, Yan Ning, Melissa Janae Labonte, Rita El-Khoueiry, Pierre Oliver Bohanes, Leonor Benhaim, David Páez, Masahiko Watanabe, Wasaburo Koizumi, Heinz-Josef Lenz
Journal: Journal of Clinical Oncology (2012)

4026 Background: AVAGAST showed regional bevacizumab (Bev) efficacy difference (RBED), namely, Asian (Asi) patients (pts) with gastric cancer (GC) had no benefit whereas European and Pan-American patients had more benefit from Bev. Recently, germline gene polymorphisms in angiogenesis have been recognized as predictive marker for Bev efficacy. Allele frequency (AF) in gene polymorphisms may vary depending on ethnicity. We tested the hypothesis whether angiogenic pathway gene polymorphisms may have different AF among Asi, Caucasian (Cau), and Hispanic (Hisp) in GC and this disparity may explain RBED. Methods: Three-hundred pts [Japanese (Jap), Cau, and Hisp, 100 from each race] with histopathologically confirmed GC were collected from Japan, USA, Austria, and Italy between 1991 and 2011. These pts were divided into 2 groups as training set (n=50) and validation set (n=50) in each race. Seven functional gene polymorphisms previously reported as predictive marker were selected. All samples were analyzed using PCR-based direct DNA- sequencing. Fisher's exact test was used to compare the distribution of AF among races. Results: Significant disparate distributions in favorable AF for Bev were shown among races in Table. Jap GC pts had significant lower AF of 5 predictive gene polymorphisms in training set, and among these 5, three predictive gene polymorphisms were also validated. Conclusions: Our preliminary results showed significant disparate AF distributions in predictive gene polymorphisms for Bev, and these disparities may explain RBED in AVAGAST. Further investigation is warranted to elucidate RBED. [Table: see text]
The syniatrist. A suggested nomenclature and classification for allied health professionals
Authors: H. K. Silver
Journal: JAMA (1971)

To clarify terminology describing allied health professionals, it is recommended that a new term, "syniatrist," defined as "an individual practicing in association, union, or together with a physician," be adopted as the generic name for health professionals who carry out functions and activities traditionally performed by physicians. The name syniatrist would apply only to health workers who have direct contact with patients in providing health care under a physician's supervision. A classification of syniatrists is proposed with two principal subdivisions: (1) area of specialty of practice, and (2) relationship of syniatrist to physician. The latter subdivision would be based on the degree of independence and competence expected from the syniatrist in the application of his professional skills.
Peer review is an effective screening process to evaluate medical manuscripts
Authors: M. Abby
Journal: JAMA (1994)

<h3>Objective.</h3> —To measure the effectiveness of peer review as a screening process to evaluate medical manuscripts. <h3>Design.</h3> —Retrospective. Setting.—The editorial office of<i>the American Journal of Surgery (AJS)</i>. <h3>Method.</h3> —A MEDLINE search was conducted of publications from 1984 to 1992 for manuscripts that were identical or similar to those rejected by<i>AJS</i>between January and December 1989. Manuscripts that were submitted to<i>AJS</i>by foreign authors were excluded because of the presumed difficulty in tracking foreign-language publications. <h3>Main Outcome Measures.</h3> —The percentage of manuscripts rejected by<i>AJS</i>that were subsequently published in journals indexed by MEDLINE, the time from rejection to ultimate publication, and the journal of publication. The reasons for rejection were also documented. We assumed that the majority of rejected manuscripts would be published within 3 years after rejection. <h3>Results.</h3> —One hundred twenty-five manuscripts submitted by North American authors were rejected by<i>AJS</i>in 1989, and 62% were not subsequently published in another core medical journal during the study period. The average duration between rejection and later publication was 17 months. Of those manuscripts subsequently published, 54% appeared in general surgical journals, including 12% that were revised, reevaluated, and later accepted by<i>AJS</i>. Twenty-nine percent of the rejected manuscripts were published in specialty medical journals, 10% in state and local journals, and the remainder in general medical journals. Twenty-eight percent of the authors of rejected manuscripts had previously and subsequently published manuscripts on very similar subjects. <h3>Conclusions.</h3> —Our data indicate that the review process serves as a sieve and influences whether manuscripts are published in core medical journals. This was demonstrated by the fact that rejected manuscripts often were not published in other indexed medical journals. (<i>JAMA</i>. 1994;272:105-107)
Geriatric Psychiatry
Authors: Frances R. Frankenburg
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endoscopic Ultrasound
Authors: I D Penman
Journal: Endoscopy (2001)

Once again, endoscopic ultrasonography (EUS) was strongly represented at this year’s Digestive Diseases Week (DDW) meeting, reflecting its ever-expanding use. Interventional EUS and new innovative roles figured prominently, and several presentations hinted at the exciting potential for further development of EUS-guided therapy in many disorders.
THE PSYCHOLOGY OF RAILROAD ACCIDENTS.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Economic Burden of Elevated Blood Glucose Levels in 2017: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes
Authors: Timothy M. Dall, Wenya Yang, Karin Gillespie, Michelle Mocarski, Erin Byrne, Inna Cintina, Kaleigh Beronja, April P. Semilla, William Iacobucci, Paul F. Hogan
Journal: Diabetes Care (2019)

This study was conducted to update national estimates of the economic burden of undiagnosed diabetes, prediabetes, and gestational diabetes mellitus (GDM) in the United States for year 2017 and provide state-level estimates. Combined with published estimates for diagnosed diabetes, these updated statistics provide a detailed picture of the economic costs associated with elevated blood glucose levels.
COMPULSORY VACCINATION CONSTITUTIONAL.
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
My Uganda
Authors: Jack Coulehan
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Die Gallensteinkrankheit, Richtlinien der inneren Klinik.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim In Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS)
Authors: Pierre Fenaux, Hagop Kantarjian, Roger M Lyons, Richard A Larson, Mikkael A Sekeres, Pamela Becker, Petra Muus, Catherine Jia, Allen S Yang
Journal: Blood (2010)
Progress Toward the Global Elimination of Neonatal Tetanus, 1989-1993
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Appropriations for City Health Departments
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Reply
Authors: Frank G. Rücker, Lars Bullinger, Konstanze Döhner, Hartmut Döhner
Journal: Journal of Clinical Oncology (2007)

deletion or UPiD in TP53 showed mutations in the gene, suggesting that TP53 may not be the principal target in de novo AML, although its role has been demonstrated to be more relevant in secondary AML. 5,6 Therefore, we think our genetic data support the proposed role of NF1 as the main target in rearrangements of chromosome 17 in de novo AML, based on previous reports, which set NF1 as a leukemogenic agent when mutated or haploinsufficient. 7,